All In Biotech

Drug Trial Radar · NCT03304379

Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip

Phase 3 Randomized, Double-Blind, Multi-Dose, Placebo And NSAID Controlled Study To Evaluate The Efficacy And Safety Of Fasinumab In Patients With Pain Due To Osteoarthritis Of The Knee Or Hip

Last checked: Nov 19, 2026Latest source record: Feb 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,650 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,650

Actual

Start

Oct 26, 2017

Primary completion

Dec 13, 2019

Study completion Nov 9, 2020

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
Collaborators
Teva Pharmaceutical Industries, Ltd.
First posted
Oct 9, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to evaluate the efficacy of fasinumab compared to placebo, when administered for up to 24 weeks in patients with pain due to osteoarthritis (OA) of the knee or hip. The secondary objectives of the study are: * To evaluate the efficacy of fasinumab compared to non-steroidal anti-inflammatory drugs (NSAID)s, when administered for up to 24 weeks in patients with pain due to OA of the knee or hip * To assess the safety and tolerability of fasinumab compared to placebo and compared to NSAIDs, when administered for up to 24 weeks in patients with pain due to OA of the knee or hip

Conditions

  • Osteoarthritis, Knee
  • Osteoarthritis, Hip

Interventions

  • FasinumabDrug

    Solution for injection in pre-filled syringe

  • DiclofenacOther

    NSAID active comparator (capsule)

  • CelecoxibOther

    NSAID active comparator (capsule)

  • Matching placeboDrug

    Fasinumab-matching placebo (solution for injection in pre-filled syringe); NSAID-matching placebo (capsule)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Scores up to Week 24 in Participants Treated With Fasinumab Compared to PlaceboTime frame: Baseline up to Week 24
  2. Change From Baseline in WOMAC Physical Function Subscale Scores up to Week 24 in Participants Treated With Fasinumab Compared to PlaceboTime frame: Baseline up to Week 24

Locations

71 sites in 1 country. Site status is shown where the registry gives one.

  • Pinnacle Research Group, Llc

    Anniston, Alabama

  • Horizon Research Partners

    Mobile, Alabama

  • Clinical Research Advantage, Inc./Warner Family Practice, PC

    Chandler, Arizona

  • Synexus Central Phoenix Medical Clinic

    Phoenix, Arizona

  • Clinical Research Consortium Arizona

    Tempe, Arizona

  • Advance Research Center

    Anaheim, California

  • TriWest Research Associates, LLC

    El Cajon, California

  • Paragon Rx Clinical Research, Inc.

    Garden Grove, California

  • Catalina Research Institute, LLC

    Montclair, California

  • Sierra Clinical Research

    Roseville, California

  • UC Davis Center for Musculoskeletal Health

    Sacramento, California

  • Advanced Research Center, Inc

    San Diego, California

  • California Research Foundation

    San Diego, California

  • Paragon Rx Clinical Research, Inc

    Santa Ana, California

  • Encompass Clinical Research

    Spring Valley, California

  • Westlake Medical Research

    Thousand Oaks, California

  • Synexus Clinical Research US, Inc.

    Vista, California

  • Mountain View Clinical Research

    Denver, Colorado

  • New England Research Associates, LLC

    Bridgeport, Connecticut

  • CRM of Greater New Haven, LLC

    Hamden, Connecticut

  • Stamford Therapeutics Consortium

    Stamford, Connecticut

  • Avail Clinical Research, LLC

    DeLand, Florida

  • AMB Research Center, Inc

    Miami, Florida

  • Allied Biomedical Research Institute

    Miami, Florida

  • Lakes Research, LLC

    Miami Lakes, Florida

  • Bioclinica Research

    Orlando, Florida

  • Gulf Region Clinical Research institute

    Pensacola, Florida

  • Integral Rheumatology & Immunology Specialists (IRIS)

    Plantation, Florida

  • Progressive Medical Research

    Port Orange, Florida

  • Drug Studies America

    Marietta, Georgia

  • Georgia Institute For Clinical Research LLC

    Marietta, Georgia

  • North Georgia Clinical Research

    Woodstock, Georgia

  • Chicago Clinical Research Institute, Inc

    Chicago, Illinois

  • Affinity Clinical Research Institute

    Oak Lawn, Illinois

  • Clinical Research Advantage, Inc.

    Evansville, Indiana

  • MediSphere Medical Research Center, LLC

    Evansville, Indiana

  • L-MARC Research Center

    Louisville, Kentucky

  • Tandem Clinical Research

    Marrero, Louisiana

  • Tufts Medical Center, Inc.

    Boston, Massachusetts

  • Great Lakes Research Group, Inc.

    Bay City, Michigan

Showing 40 of 71 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.